Table 1

Biodistribution study of radiolabeled annexin V after anti-Fas antibody treatment

A)99mTc % IDControls (n = 9)1-hr anti-Fas (n = 15)2-hr anti-Fas (n = 12)
Liver12.2  ±  1.428.6  ±  9.4**49.3  ±  12.7***
Kidneys55.9  ±  8.935.2  ±  14.4**14.0  ±  10.0***
Spleen1.6  ±  0.253.34  ±  1.42*2.46  ±  1.22(ns)
B)125I % IDControls (n = 4)1-hr anti-Fas (n = 6)2-hr anti-Fas (n = 5)
Liver3.98  ±  1.098.77  ±  3.53*8.4  ±  1.92*
Kidneys1.37  ±  0.351.88  ±  0.37(ns)1.82  ±  0.38(ns)
Spleen0.39  ±  0.090.47  ±  0.15(ns)0.37  ±  0.041(ns)
C)Weight (grams)Controls (n = 9)1-hr anti-Fas (n = 15)2-hr anti-Fas (n = 12)
Liver1.06  ±  0.0971.29  ±  0.32(ns)1.37  ±  0.22*
Kidneys0.31  ±  0.0610.32  ±  0.079(ns)0.37  ±  0.072(ns)
Spleen0.12  ±  0.0220.12  ±  0.02(ns)0.11  ±  0.014(ns)
  • % injected dose (ID) per organ corrected for background, decay, and tail infiltration are listed for mice injected with 100–150 μCi (radiopurity >95%, specific activity 150–200 μCi/μg protein) of 99mTc HYNIC-annexin co-injected with 0.6 μCi (25 mg) of 125I radiolabeled HSA. A) Biodistribution of 99m Tc HYNIC-annexin V, B) 125-HSA, and C) Organ weight. Data are expressed as mean ± standard error of the mean. P-values are shown in parenthesis () for Dunnett’s test for multiple comparison of means of the 1- or 2-hr post-treatment groups compared with control. ns, not significant (i.e., P-value > 0.05); ∗, P < 0.05; ∗∗, P < 0.001; ∗∗∗, P < 0.0001.